Utilizing a CNS Penetrant MasterKey Inhibitor to Access the Blood Brain Barrier to Treat Glioblastoma & Brain Metastasis in NSCLC

Time: 10:00 am
day: Day Two


  • Revealing BDTX-1535, a CNS penetrant MasterKey inhibitor of EGFR mutations which demonstrates in vivo efficacy and has the potential to treat patients with NSCLC and GBM
  • Targeting unmet medical needs in EGFR-mutated NSCLC EGFR-mutated GBM
  • Presenting preclinical data that support opportunity for progression to clinical studies and therapeutic effect in both indications